Evidence map›Paper›PMID 23099282›Full record

SynthesisNeuroscience and biobehavioral reviews2013

Systematic review: pharmacological treatment of tic disorders--efficacy of antipsychotic and alpha-2 adrenergic agonist agents.

Hannah Weisman, Imraan A Qureshi, James F Leckman, Lawrence Scahill, Michael H Bloch

Registry-linked trialAbstract readSystematic Review
In one paragraph

Synthesis in Neuroscience and biobehavioral reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04794413 (An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome), which is not on this map. Cited by 55 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 7 pooled it
15.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04794413 early_phase1completednot on this mapstarted 2018, after this paper: background citation

An Open Label, Proof-of-Principle, Pilot Study to Evaluate Pimavanserin for the Treatment of Motor and Behavioral Symptoms of Tourette Syndrome

TypeinterventionalSponsorJoseph JankovicRan2018 to 2021Enrolled10ConditionsTourette Syndrome, Tardive DyskinesiaArmsPimavanserin
3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 7 syntheses or guidelines pooled it, 232 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Assessment and management of treatment-refractory obsessive-compulsive disorder in children.Journal of the American Academy of Child and Adolescent Psychiatry · 2015
    Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Tourette syndrome.Nature reviews. Disease primers · 2026
    Review
  15. Article
  16. Article
  17. Activation of MBritish journal of pharmacology · 2024
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Hannah WeismanYale Child Study Center, Yale University School of Medicine, New Haven, CT 06520, USA.
Imraan A Qureshi
James F Leckman
Lawrence Scahill
Michael H Bloch
Yale University · US

Funding

YALE UNIVERSITY CLINICAL AND TRANSLATIONAL SCIENCE AWARD PROGRAMUL1RR024139 · NCRR · YALE UNIVERSITY · PI SHERWIN, ROBERT S · 2006 to 2011
$56.8M
Research Training for Medical Students & Physician-Scientists in Child PsychiatryR25MH077823 · NIMH · YALE UNIVERSITY · PI ANDRES S MARTIN · 2006 to 2026
$4.0M
RUPP-PI Program at Yale UniversityU10MH066764 · NIMH · YALE UNIVERSITY · PI SCAHILL, LAWRENCE D. · 2002 to 2006
$2.5M
4/4-RUPP Autism Network: Guanfacine for the Treatment of Hyperactivity in PDDR01MH083707 · NIMH · YALE UNIVERSITY · PI SCAHILL, LAWRENCE D. · 2010 to 2013
$1.3M
Longitudinal Structural MRI Study of Adulthood Outcome in Tourette SyndromeK23MH091240 · NIMH · YALE UNIVERSITY · PI BLOCH, MICHAEL H · 2010 to 2014
$902k
NCRR NIH HHS UL1 RR024139NIMH NIH HHS K23 MH091240NIMH NIH HHS K23MH091240NIMH NIH HHS R01 MH083707NIMH NIH HHS R25 MH077823NIMH NIH HHS U10 MH066764NIMH NIH HHS U10MH66764
6 · The paper itself

Abstract

We conducted a meta-analysis of randomized, placebo-controlled trials to determine the efficacy of antipsychotic and alpha-2 agonists in the treatment of chronic tic disorders and examine moderators of treatment effect. Meta-analysis demonstrated a significant benefit of antipsychotics compared to placebo (standardized mean difference (SMD)=0.58 (95% confidence interval (CI): 0.36-0.80). Stratified subgroup analysis found no significant difference in the efficacy of the 4 antipsychotic agents tested (risperidone, pimozide, haloperidol and ziprasidone). Meta-analysis also demonstrated a benefit of alpha-2 agonists compared to placebo (SMD=0.31 (95% confidence interval CI: 0.15-0.48). Stratified subgroup analysis and meta-regression demonstrated a significant moderating effect of co-occurring ADHD. Trials which enrolled subjects with tics and ADHD demonstrated a medium-to-large effect (SMD=0.68 (95%CI: 0.36-1.01) whereas trials that excluded subjects with ADHD demonstrated a small, non-significant benefit (SMD=0.15 (95%CI: -0.06 to 0.36). Our findings demonstrated significant benefit of both antipsychotics and alpha-2 agonists in treating tics but suggest alpha-2 agonists may have minimal benefit in tic patients without ADHD.

Indexed as

Adrenergic alpha-AgonistsAge FactorsAnimalsAntidiarrhealsAttention Deficit Disorder with HyperactivityClinical Trials as TopicHumansMeta-Analysis as TopicPubMedTic DisordersAdrenergic alpha-AgonistsAntidiarrheals

Identifiers

PMID23099282
PMCPMC3674207
OpenAlexW2050751727

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.